Access to systemic treatment of non-melanoma skin cancer in Spain: a survey analysis

被引：0

作者：

Cerezuela-Fuentes, Pablo ^{[1
]}

Gonzalez-Cao, Maria ^{[2
]}

Puertolas, Teresa ^{[3
]}

Manzano, Jose Luis ^{[4
]}

Maldonado, Cayetana ^{[5
]}

Yelamos, Oriol ^{[6
]}

Berciano-Guerrero, Miguel A. ^{[7
]}

Martin-Liberal, Juan ^{[8
]}

Munoz-Couselo, Eva ^{[9
]}

Espinosa, Enrique ^{[10
,11
]}

Drozdowskyj, Ana ^{[1
]}

Berrocal, Alfonso ^{[12
]}

Soria, Ainara ^{[13
]}

Marquez-Rodas, Ivan ^{[14
]}

Martin-Algarra, Salvador ^{[15
]}

Quindos, Maria ^{[16
]}

Puig, Susana ^{[11
,17
]}

机构：

[1] Hosp Clin Univ Virgen Arrixaca, Oncol Dept, Inst Murciano Invest Biosanitaria IMIB, Murcia, Spain

[2] Dexeus Univ Hosp, Dr Rosell Oncol Inst IOR, Translat Canc Res Unit, C Sabino Arana,5, Barcelona 080028, Spain

[3] Hosp Miguel Servet, Oncol Dept, Zaragoza, Spain

[4] Hosp Badalona Germans Trias & Pujol, Catalan Inst Oncol ICO Badalona, Badalona, Spain

[5] Hosp Univ Asturias, Dermatol Dept, Oviedo, Spain

[6] Hosp Santa Creu & Sant Pau, Dermatol Dept, Barcelona, Spain

[7] Univ Reg & Virgen Victoria HURyVV, Oncol Dept Hosp, Inst Invest Biomed Malaga IBIMA, Malaga, Spain

[8] Hosp Duran i Reynals, Catalan Inst Oncol ICO Hosp, Barcelona, Spain

[9] Hosp Valle De Hebron, Oncol Dept, Barcelona, Spain

[10] Hosp Univ la Paz, Oncol Dept, Madrid, Spain

[11] CIBERER, Barcelona, Spain

[12] Hosp Gen Valencia, Oncol Dept, Valencia, Spain

[13] Hosp Ramon & Cajal, Oncol Dept, Madrid, Spain

[14] Hosp Gen Univ Gregorio Maranon, Oncol Dept, Madrid, Spain

[15] Clin Univ Navarra, Oncol Dept, Pamplona, Spain

[16] Complexo Hosp Univ A Coruna, Biomed Res Inst INIBIC, Med Oncol Dept, La Coruna, Spain

[17] Univ Barcelona, Hosp Clin Barcelona, Dermatol Dept, IDIBAPS, Barcelona 08023, Spain

来源：

CLINICAL & TRANSLATIONAL ONCOLOGY | 2025年 / 27卷 / 01期

关键词：

Non-melanoma skin cancer; Access; Innovative therapies; MULTICENTER;

D O I：

10.1007/s12094-024-03583-5

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BackgroundNovel and highly effective drugs for non-melanoma skin cancer (NMSC) improve patient outcomes, but their high cost strains healthcare systems. Spain's decentralized public health system, managed by 17 autonomous communities (AaCc), raises concerns about equitable access.MethodsA cross-sectional survey (July-September 2023) was sent to Spanish Multidisciplinary Melanoma Group (GEM Group) members to assess access to new drugs.FindingsFifty physicians from 15 Spanish AaCc responded to the survey. Access for drug with approved public reimbursement, Hedgehog inhibitors in basal-cell carcinoma and anti PD-L1 antibody in Merkel carcinoma, was observed in 84% and 86% of centers, respectively. For other EMA-approved treatments, but without reimbursement in Spain access decreased to 78% of centers. Heterogeneity in access was mainly observed intra regions.ConclusionUnequal financial support for drugs for NMSC with creates a patchwork of access across Spanish hospitals, with variations even within the same AaCc.

引用

页码：386 / 391

页数：6

共 17 条

[1] Difficulties on the access to innovative targeted therapies for lung cancer in Spain [J].

Calvo, Virginia ;

Camps, Carlos ;

Carcereny, Enric ;

Cobo, Manuel ;

Domine, Manuel ;

Garcia Campelo, Maria Rosario ;

Gonzalez Larriba, Jose Luis ;

Guirado, Maria ;

Hernando-Trancho, Florentino ;

Massuti, Bartomeu ;

Nadal, Ernest ;

Rodriguez-Abreu, Delvys ;

Sanchez, Alfredo ;

Sullivan, Ivana Gabriela ;

Provencio, Mariano .

CLINICAL & TRANSLATIONAL ONCOLOGY, 2023, 26 (3) :597-612

[2] Pembrolizumab for advanced basal cell carcinoma: An investigator-initiated, proof-of-concept study [J].

Chang, Anne Lynn S. ;

Tran, Duy C. ;

Cannon, John G. D. ;

Li, Shufeng ;

Jeng, Mark ;

Patel, Roma ;

Van der Bokke, Lindsay ;

Pague, Alana ;

Brotherton, Richard ;

Rieger, Kerri E. ;

Satpathy, Ansuman T. ;

Yost, Kathryn E. ;

Reddy, Sunil ;

Sarin, Kavita ;

Colevas, A. Dimitrios .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 80 (02) :564-566

[3] Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma [J].

D'Angelo, Sandra P. ;

Hunger, Matthias ;

Brohl, Andrew S. ;

Nghiem, Paul ;

Bhatia, Shailender ;

Hamid, Omid ;

Mehnert, Janice M. ;

Terheyden, Patrick ;

Shih, Kent C. ;

Brownell, Isaac ;

Lebbe, Celeste ;

Lewis, Karl D. ;

Linette, Gerald P. ;

Milella, Michele ;

Schlichting, Michael ;

Hennessy, Meliessa H. ;

Bharmal, Murtuza .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2019, 68 (04) :609-618

[4]

EFPIA. European Federation of Pharmaceutical Industries and Associations (EFPIA), 2022, EFPIA PATIENTS WAIT

[5]

GEPAC, 2023, CANC CUESTION ESTADO

[6] Access to melanoma drugs in Spain: a cross-sectional survey [J].

Gonzalez-Cao, Maria ;

Puertolas, Teresa ;

Manzano, Jose Luis ;

Maldonado, Cayetana ;

Yelamos, Oriol ;

Berciano-Guerrero, Miguel angel ;

Cerezuela, Pablo ;

Martin-Liberal, Juan ;

Munoz-Couselo, Eva ;

Espinosa, Enrique ;

Drozdowskyj, Ana ;

Berrocal, Alfonso ;

Soria, Ainara ;

Marquez-Rodas, Ivan ;

Martin-Algarra, Salvador ;

Quindos, Maria ;

Puig, Susana .

CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (10) :2572-2583

[7] Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial [J].

Hughes, B. G. M. ;

Munoz-Couselo, E. ;

Mortier, L. ;

Bratland, A. ;

Gutzmer, R. ;

Roshdy, O. ;

Mendoza, R. Gonzalez ;

Schachter, J. ;

Arance, A. ;

Grange, F. ;

Meyer, N. ;

Joshi, A. ;

Billan, S. ;

Zhang, P. ;

Gumuscu, B. ;

Swaby, R. F. ;

Grob, J. -j. .

ANNALS OF ONCOLOGY, 2021, 32 (10) :1276-1285

[8] Systemic Therapy in Advanced Cutaneous Squamous Cell Carcinoma (CSCC) The Roswell Park Experience and a Review of the Literature [J].

Jarkowski, Anthony, III ;

Hare, Ryan ;

Loud, Peter ;

Skitzki, Joseph J. ;

Kane, John M., III ;

May, Kilian S. ;

Zeitouni, Nathalie C. ;

Nestico, Jill ;

Vona, Karen L. ;

Groman, Adrienne ;

Khushalani, Nikhil I. .

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2016, 39 (06) :545-548

[9] PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma [J].

Migden, M. R. ;

Rischin, D. ;

Schmults, C. D. ;

Guminski, A. ;

Hauschild, A. ;

Lewis, K. D. ;

Chung, C. H. ;

Hernandez-Aya, L. ;

Lim, A. M. ;

Chang, A. L. S. ;

Rabinowits, G. ;

Thai, A. A. ;

Dunn, L. A. ;

Hughes, B. G. M. ;

Khushalani, N. I. ;

Modi, B. ;

Schadendorf, D. ;

Gao, B. ;

Seebach, F. ;

Li, S. ;

Li, J. ;

Mathias, M. ;

Booth, J. ;

Mohan, K. ;

Stankevich, E. ;

Babiker, H. M. ;

Brana, I. ;

Gil-Martin, M. ;

Homsi, J. ;

Johnson, M. L. ;

Moreno, V. ;

Niu, J. ;

Owonikoko, T. K. ;

Papadopoulos, K. P. ;

Yancopoulos, G. D. ;

Lowy, I. ;

Fury, M. G. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (04) :341-351

[10] Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial [J].

Migden, Michael R. ;

Guminski, Alexander ;

Gutzmer, Ralf ;

Dirix, Luc ;

Lewis, Karl D. ;

Combemale, Patrick ;

Herd, Robert M. ;

Kudchadkar, Ragini ;

Trefzer, Uwe ;

Gogov, Sven ;

Pallaud, Celine ;

Yi, Tingting ;

Mone, Manisha ;

Kaatz, Martin ;

Loquai, Carmen ;

Stratigos, Alexander J. ;

Schulze, Hans-Joachim ;

Plummer, Ruth ;

Chang, Anne Lynn S. ;

Cornelis, Frank ;

Lear, John T. ;

Sellami, Dalila ;

Dummer, Reinhard .

LANCET ONCOLOGY, 2015, 16 (06) :716-728

← 1 2 →